Ved monitorering af patientens faktor VIII- aktivitet under behandling med ReFacto AF anbefales det kraftigt at anvende den Europæiske Farmakopés kromogeniske substratanalyse.
When monitoring patients' factor VIII activity levels during treatment with ReFacto AF, use of the European Pharmacopoeial chromogenic substrate assay is strongly recommended.